이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Pharma Mar 미래 성장

Future 기준 확인 5/6

Pharma Mar (는) 각각 연간 47.7% 및 16.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 1.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 29.6% 로 예상됩니다.

주요 정보

46.4%

수익 성장률

1.4%

EPS 성장률

Biotechs 수익 성장	33.8%
매출 성장률	17.8%
향후 자기자본 수익률	33.7%
애널리스트 커버리지	Low
마지막 업데이트	22 Jul 2024

최근 미래 성장 업데이트

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 03

Recent updates

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Jun 01

Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

May 28

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 03

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Jan 25

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Apr 28

We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Mar 08

An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Sep 27

Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Jul 15

Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

May 04

Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

Apr 11

There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Mar 16

Is Pharma Mar (BME:PHM) Using Too Much Debt?

Jan 09

Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

Sep 08

News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Aug 03

Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

May 31

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

May 10

Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 08

Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Jan 14

Is Pharma Mar (BME:PHM) A Risky Investment?

Nov 19

수익 및 매출 성장 예측

BME:PHM - 애널리스트의 미래 추정치 및 과거 재무 데이터 (EUR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	237	92	98	110	4
12/31/2025	198	59	63	73	4
12/31/2024	165	7	13	21	4
3/31/2024	162	2	-35	-12	N/A
12/31/2023	158	1	-29	-13	N/A
9/30/2023	168	14	-29	-13	N/A
6/30/2023	175	21	-14	-1	N/A
3/31/2023	177	29	N/A	N/A	N/A
12/31/2022	196	49	29	38	N/A
9/30/2022	235	79	N/A	N/A	N/A
6/30/2022	233	85	41	48	N/A
3/31/2022	232	91	N/A	N/A	N/A
12/31/2021	230	93	18	26	N/A
9/30/2021	188	63	N/A	N/A	N/A
6/30/2021	200	67	19	24	N/A
3/31/2021	222	91	113	117	N/A
12/31/2020	270	137	276	279	N/A
9/30/2020	246	147	264	270	N/A
6/30/2020	214	124	255	259	N/A
3/31/2020	166	72	161	165	N/A
12/31/2019	86	-9	-28	-24	N/A
9/30/2019	136	-27	-24	-23	N/A
6/30/2019	84	-37	-12	-12	N/A
3/31/2019	154	-24	-24	-22	N/A
12/31/2018	109	-17	-19	-17	N/A
9/30/2018	189	-16	-23	-20	N/A
6/30/2018	128	-20	-27	-22	N/A
3/31/2018	179	-26	-24	-19	N/A
12/31/2017	159	-28	N/A	-1	N/A
9/30/2017	182	-22	N/A	4	N/A
6/30/2017	186	-18	N/A	9	N/A
3/31/2017	184	-19	N/A	13	N/A
12/31/2016	181	-24	N/A	-8	N/A
9/30/2016	187	-18	N/A	N/A	N/A
6/30/2016	188	-10	N/A	5	N/A
3/31/2016	190	-7	N/A	N/A	N/A
12/31/2015	194	7	N/A	11	N/A
12/31/2014	175	13	N/A	23	N/A
12/31/2013	74	12	N/A	74	N/A

애널리스트 미래 성장 예측

수입 대 저축률: PHM 의 연간 예상 수익 증가율( 47.7% )이 saving rate( 1.5% 보다 높습니다. ).

수익 vs 시장: PHM 의 연간 수익( 47.7% ) Spanish 시장( 9.4% 보다 빠르게 성장할 것으로 예상됩니다. 9.4% 연간).

고성장 수익: PHM 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: PHM 의 수익(연간 16.1% ) Spanish 시장( 4.7% 보다 빠르게 성장할 것으로 예상됩니다. 4.7% 연간).

고성장 수익: PHM 의 수익(연간 16.1% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: PHM 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 29.6 %)

Pharma Mar 미래 성장

Future 기준 확인 5/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates increase by 149%

Consensus EPS estimates fall by 76%

Consensus EPS estimates fall by 29%

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Consensus EPS estimates fall by 78%

Price target decreased by 9.1% to €49.83

Recent updates

Consensus EPS estimates increase by 149%

Pharma Mar Presents Encouraging Results At ASCO for Small Cell Lung Cancer

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

Consensus EPS estimates fall by 76%

Dividend of €0.53 announced

Consensus EPS estimates fall by 29%

New major risk - Dividend sustainability

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings released: EPS: €0.06 (vs €2.73 in FY 2022)

Consensus EPS estimates fall by 78%

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Price target decreased by 9.1% to €49.83

Consensus EPS estimates fall by 13%, revenue upgraded

New major risk - Earnings quality

Second quarter 2023 earnings released

Price target decreased by 7.4% to €54.83

Consensus EPS estimates fall by 35%

Price target decreased by 9.7% to €57.17

Consensus EPS estimates fall by 22%

Pharma Mar, S.A., Annual General Meeting, May 31, 2023

Price target decreased by 11% to €61.20

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 23%, revenue upgraded

Now 20% undervalued after recent price drop

We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Consensus revenue estimates fall by 11%

Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 21%

Price target decreased by 7.6% to €71.03

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Consensus EPS estimates fall by 17%, revenue upgraded

Now 20% undervalued

Pharma Mar, S.A.(BME:PHM) dropped from Madrid Ibex 35 Index

Now 20% undervalued

High number of new directors

Consensus forecasts updated

We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Now 21% undervalued after recent price drop

Consensus forecasts updated

Investor sentiment deteriorated over the past week

High number of new directors

Pharma Mar, S.A. to Report Q2, 2022 Results on Jul 27, 2022

Second quarter 2022 earnings released

High number of new directors

Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Upcoming dividend of €0.53 per share

Investor sentiment deteriorated over the past week

Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

Consensus forecasts updated

Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analyst expectations

Investor sentiment improved over the past week

Pharma Mar, S.A. to Report Q4, 2021 Results on Feb 28, 2022

Pharma Mar, S.A. Announces Publication of an Article in the Life Science Alliance Journal, Entitled "Pre-Clinical and Randomized Phase I Studies of Plitidepsin in Adults Hospitalized with Covid-19

Investor sentiment improved over the past week

Is Pharma Mar (BME:PHM) Using Too Much Debt?

PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer

Jazz Pharmaceuticals plc and PharmaMar Announces Commercial Availability in Canada of Zepzelca™ (Lurbinectedin)

Price target decreased to €91.47

Price target decreased to €101

Third quarter 2021 earnings released

Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Second quarter 2021 earnings released